CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals (NASDAQ:CASI) received a delisting determination dated November 5, 2025 from Nasdaq after failing to meet the minimum market value of listed securities (MVLS) $35 million requirement for the applicable period. Nasdaq had notified CASI on May 5, 2025 that its MVLS fell below the $35 million threshold and provided a 180-calendar-day compliance period ending November 3, 2025.
The company has appealed the delisting determination and requested a hearing to present a plan to regain compliance; the appeal will stay the suspension of the company's securities. CASI says it is in dialogue with Nasdaq and will provide material updates to shareholders as available.
CASI Pharmaceuticals (NASDAQ:CASI) ha ricevuto una delisting determination datata 5 novembre 2025 da Nasdaq dopo non aver rispettato il requisito minimo valore di mercato delle securities quotate (MVLS) di 35 milioni di dollari per il periodo applicabile. Nasdaq aveva comunicato a CASI il 5 maggio 2025 che il MVLS era sceso al di sotto della soglia di 35 milioni e aveva fornito un periodo di conformità di 180 giorni di calendario che terminava 3 novembre 2025.
L'azienda ha presentato ricorso contro la delisting e richiesto un'udienza per esporre un piano per ripristinare la conformità; l'appello farà sì che la sospensione dei titoli della società resti sospesa. CASI dice che è in dialogo con Nasdaq e fornirà aggiornamenti sostanziali agli azionisti non appena disponibili.
CASI Pharmaceuticals (NASDAQ:CASI) recibió una determinación de exclusión del listado fechada el 5 de noviembre de 2025 de Nasdaq tras no cumplir con el requisito mínimo valor de mercado de valores cotizados (MVLS) de 35 millones de dólares para el periodo aplicable. Nasdaq había notificado a CASI el 5 de mayo de 2025 que su MVLS se había situado por debajo del umbral de 35 millones y proporcionó un periodo de cumplimiento de 180 días naturales que terminaba el 3 de noviembre de 2025.
La compañía ha apelado la determinación de exclusión y ha solicitado una audiencia para presentar un plan para volver a cumplir; la apelación mantendrá la suspensión de los valores de la empresa. CASI afirma que está en diálogo con Nasdaq y proporcionará actualizaciones materiales a los accionistas conforme estén disponibles.
CASI Pharmaceuticals (NASDAQ:CASI)이 2025년 11월 5일자 상장폐지 결정을 Nasdaq로부터 받아 해당 기간의 상장주식 시가총액 MVLS 3,500만 달러 요건을 충족하지 못했기 때문입니다. Nasdaq는 2025년 5월 5일에 CASI의 MVLS가 3,500만 달러 임계값 아래로 떨어졌다고 통지했고 180일의 달력 기간을 제공했으며 이 기간은 2025년 11월 3일에 만료되었습니다.
회사는 상장폐지 결정에 대한 항소를 제기했고 복귀를 위한 계획을 제시하기 위한 청문회를 요청했습니다; 항소는 회사의 증권 거래 중단을 유지시킬 것입니다. CASI는 Nasdaq와 대화를 진행중이며 가능하면 주주들에게 중요한 업데이트를 제공하겠다고 밝히고 있습니다.
CASI Pharmaceuticals (NASDQAQ:CASI) a reçu une décision de radiation datée du 5 novembre 2025 de Nasdaq après ne pas avoir respecté l’exigence minimale de valeur marchande des valeurs cotées (MVLS) de 35 millions de dollars pour la période applicable. Nasdaq avait informé CASI le 5 mai 2025 que son MVLS était inférieur au seuil de 35 millions et avait accordé une période de conformité de 180 jours calendaires se terminant le 3 novembre 2025.
La société a fait appel de la décision de radiation et a demandé une audience pour présenter un plan visant à rétablir la conformité; l’appel fera suspendre la suspension des titres de la société. CASI indique qu’elle est en dialogue avec Nasdaq et fournira des mises à jour importantes aux actionnaires dès que disponibles.
CASI Pharmaceuticals (NASDAQ:CASI) hat von Nasdaq eine Delisting-Bescheidung datiert vom 5. November 2025 erhalten, weil sie die Mindestanforderung Marktkapitalisierung der gelisteten Wertpapiere (MVLS) von 35 Millionen US-Dollar für den geltenden Zeitraum nicht erfüllt hat. Nasdaq hatte CASI am 5. Mai 2025 mitgeteilt, dass MVLS unter dem Schwellenwert von 35 Millionen lag, und einen 180 Kalendertage-Compliance-Zeitraum gewährt, der am 3. November 2025 endete.
Das Unternehmen hat Widerspruch gegen die Delisting-Bescheidung eingelegt und eine Anhörung beantragt, um einen Plan zur Wiederherstellung der Konformität vorzulegen; der Einspruch wird die Suspension der Wertpapiere des Unternehmens aussetzen. CASI teilt mit, dass es im Dialog mit Nasdaq steht und den Aktionären, sobald verfügbar, substanzielle Updates geben wird.
CASI Pharmaceuticals (NASDAQ:CASI) حصلت على قرار سحب الإدراج بتاريخ 5 نوفمبر 2025 من ناسداك بعد فشلها في تحقيق الحد الأدنى لقيمة السوقية للأوراق المالية المدرجة (MVLS) البالغة 35 مليون دولار للمدة المعنية. كانت ناسداك قد أبلغت CASI في 5 مايو 2025 بأن MVLS لديها انخفض عن عتبة 35 مليون دولار وقدمت فترة امتثال من 180 يوماً تقويمياً تُنتهي في 3 نوفمبر 2025.
Company has رفعت دعوى ضد قرار الإزالة وطلبت جلسة استماع لعرض خطة لاستعادة الامتثال؛ ستؤدي الطعن إلى إيقاف تعليق أوراق الشركة. وتذكر CASI أنها في حوار مع Nasdaq وستقدم تحديثات مادية للمساهمين عند توافرها.
- Company filed an appeal and requested a hearing to regain compliance
- Appeal process will stay suspension of the company’s securities
- MVLS fell below the required $35 million threshold
- Failed to regain compliance during the 180-day period ending November 3, 2025
- Received Nasdaq delisting determination on November 5, 2025
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a letter dated November 5, 2025, with a delisting determination from Nasdaq Stock Market LLC (the "Determination").
As previously reported, on May 5, 2025, Nasdaq notified the Company that its market value of listed securities (MVLS) had fallen below the minimum requirement of
CASI has already appealed this Determination and requested a hearing on the matter to present a detailed plan to Nasdaq to regain compliance, seeking a further extension of grace period to comply with the Nasdaq MVLS requirement. This appeal will stay the suspension of the Company's securities.
CASI remains committed to ensuring compliance and maintaining our Nasdaq listing. We are in constructive dialogue with Nasdaq regarding the process to regain compliance and will provide material updates to shareholders as they become available.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.
More information on CASI is available at www.casipharmaceuticals.com.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "future," "intends," "plans," "believes," and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the possibility that we may be delisted from trading on The Nasdaq Capital Market if we are not granted any extension of compliance period; uncertainties related to the possibility that the transaction for the divestiture of certain assets in China (the "Transaction") will not occur as planned if events arise that result in the termination of the Equity and Assets Transfer Agreement, or if one or more of the various closing conditions to the Transaction are not satisfied or waived; the possibility that our plan with respect to our business operations after the consummation of the Transaction can be implemented successfully; our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to receive approval for renewal of license of our existing products; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; the risk related to the Company's ongoing development of and regulatory application for CID-103 with respect to the treatment of antibody-mediated rejection for organ transplant and the license arrangements of CID-103; risks relating to interests of our largest shareholder and our Chairman that differ from our other shareholders; risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd.; and risks related to our disagreement with Acrotech with respect to the termination of agreements regarding EVOMELA®. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.
EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN®is proprietary to Acrotech Biopharma Inc and its affiliates. The Company is currently involved in disputes and legal proceedings related to certain pipeline products, including EVOMELA® and CNCT-19.Please refer to the Company's earlier SEC filing for further information.
INVESTOR CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
What did CASI (NASDAQ:CASI) receive from Nasdaq on November 5, 2025?
Why did Nasdaq issue a delisting determination for CASI (NASDAQ:CASI)?
What compliance period did CASI (NASDAQ:CASI) have to regain MVLS?
Has CASI (NASDAQ:CASI) appealed the Nasdaq delisting determination?
Does CASI’s appeal stop Nasdaq from suspending its securities?
